Sirolimus Modifies Cholesterol Homeostasis in Hepatic Cells: A Potential Molecular Mechanism for Sirolimus-Associated Dyslipidemia
Authors:
- 27 October 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 84 (8) , 1029-1036
Abstract
Background. Sirolimus is a potent immunosuppressive agent, which is associated with dyslipidemia in clinical transplantation. The present study was undertaken to investigate the potential hepatocyte mechanisms by which sirolimus causes dyslipidemia. Methods. Using both a quantitative assay of intracellular cholesterol and an [3H]-labeled cholesterol efflux assay, we studied the effect of sirolimus on cholesterol accumulation and cholesterol efflux in HepG2 cells in the absence or presence of inflammatory stress induced by interleukin-1β. The gene and protein expression of molecules involved in cholesterol homeostasis were examined by real-time reverse-transcription polymerase chain reaction and Western blotting. Results. Sirolimus inhibited low-density lipoprotein (LDL) receptor (LDLr)-mediated cholesterol ester accumulation induced by interleukin-1β in HepG2 cells. This inhibitory effect was mediated by down-regulation of sterol regulatory element-binding proteins (SREBP) cleavage activating protein (SCAP) and SREBP-2 mRNA expression. Using confocal microscopy, we demonstrated that sirolimus reduced translocation of SCAP-SREBP2 complex from endoplasmic reticulum to Golgi for activation, thereby inhibiting LDLr gene transcription. Reduction of LDLr in the liver may result in a delay of LDL-cholesterol clearance from circulation causing an increase of plasma cholesterol concentration. Furthermore, sirolimus increased cholesterol efflux mediated by adenosine triphosphate-binding cassette transporter A1 gene expression by increasing peroxisome proliferator-activated receptor-α and liver X receptor-α gene and protein expression. Increased cholesterol efflux from HepG2 cells may increase high-density lipoprotein cholesterol level and also contribute to apolipoprotein B lipoprotein formation by enhancing transfer of high-density lipoprotein cholesterol to apolipoprotein B lipoproteins. Conclusions. This study demonstrates that the increase of LDL cholesterol by sirolimus is partly due to the reduction of LDLr on hepatocytes.Keywords
This publication has 22 references indexed in Scilit:
- Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2006
- Low Incidence of Malignancy among Sirolimus/Cyclosporine-Treated Renal Transplant RecipientsTransplantation, 2005
- Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group StudyJournal of Clinical Oncology, 2005
- Transcriptional regulatory networks in lipid metabolism control ABCA1 expressionBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005
- Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine–based immunosuppressive regimen: incidence, risk factors, progression, and prognosis1Transplantation, 2003
- Protective Effect of the Immunosuppressant Sirolimus Against Aortic Atherosclerosis In Apo E-Deficient MiceAmerican Journal of Transplantation, 2003
- Effects of Sirolimus on Lipids in Renal Allograft Recipients: An Analysis Using the Framingham Risk ModelAmerican Journal of Transplantation, 2002
- Hyperlipidaemia and post‐heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin ANephrology Dialysis Transplantation, 2000
- Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and GolgiProceedings of the National Academy of Sciences, 1999
- PREVALENCE OF DYSLIPIDEMIA IN LIVER TRANSPLANT RECIPIENTSTransplantation, 1992